NCT02060526View on ClinicalTrials.gov

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 26, 2014

Primary Completion Date

June 1, 2016

Study Completion Date

June 1, 2016

Conditions
Sanfilippo Syndrome
Interventions
DRUG

Recombinant human heparan N-sulfatase [rhHNS]

Recombinant human heparan N-sulfatase \[rhHNS\]

Trial Locations (10)

20246

Universitätsklinikum Hamburg Eppendorf, Hamburg

22660

Academisch Medisch Centrum, Amsterdam

27514

University of North Carolina, Chapel Hill

55455

University of Minnesota Department of Pediatrics, Minneapolis

90502

Los Angeles Biomedical Research, Torrance

94270

Chu Bicetre, Le Kremlin-Bicêtre

Unknown

Hospital Universitario Austral A Unidad de Investigacion, Buenos Aires

U.O.S Malattie Metaboliche Rare Clinical Pediatrica, Monza

08035

Hospital Vall D'Hebron, Barcelona

WC1N 3JH

Great Ormond Street Hospital, London

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT02060526 - Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease | Biotech Hunter | Biotech Hunter